Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKE | Q14164 | 14/20 | 1.00 |
| ▸ | PLK1 | P53350 | 9/20 | 1.00 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 1.00 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gsk-319347A SCHEMBL29712606 | 1.00 | IKBKE (1.00) | IKBKEPLK1TBK1PLK3 | |
| Gsk-319347A SCHEMBL29493088 | 1.00 | IKBKE (1.00) | IKBKEPLK1TBK1PLK3 | |
| SCHEMBL4032804 | 0.88 | IKBKE (0.80) | IKBKEPLK1TBK1PLK3 | |
| SCHEMBL13575282 | 0.86 | PLK1 (0.78) | IKBKEPLK1TBK1PLK3 | |
| SCHEMBL4041358 | 0.83 | PLK1 (1.00) | IKBKEPLK1TBK1PLK3 | |
| SCHEMBL4038453 | 0.83 | IKBKE (1.00) | IKBKEPLK1TBK1PLK3 | |
| SCHEMBL4033041 | 0.82 | IKBKE (0.79) | IKBKEPLK1TBK1PLK3 | |
| SCHEMBL4032648 | 0.80 | IKBKE (0.70) | IKBKEPLK1TBK1PLK3 | |
| SCHEMBL4036540 | 0.79 | PLK1 (0.68) | IKBKEPLK1TBK1 | |
| SCHEMBL4032882 | 0.79 | IKBKE (0.69) | IKBKEPLK1TBK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4682248-A1 | NEW HUMAN TISSUE ORGANOID CULTURE SYSTEM | Peking University (CN) | 2026-01-21 | — | — | EP | claimed |
| WO-2024193486-A1 | NEW HUMAN TISSUE ORGANOID CULTURE SYSTEM | 北京大学 | 2024-09-26 | — | — | WO | claimed |
| US-20190264228-A1 | TRANSFECTION METHOD COMPRISING NONVIRAL GENE DELIVERY SYSTEMS | KARL ROSA (DE) | 2019-08-29 | — | — | US | claimed |
| EP-3490608-A1 | TRANSFECTION METHOD COMPRISING NONVIRAL GENE DELIVERY SYSTEMS | Karl, Rosa (DE) | 2019-06-05 | — | — | EP | claimed |
| EP-1720864-B1 | BENZIMIDAZOL SUBSTITUTED THIOPHENE DERIVATIVES WITH ACTIVITY ON IKK3 | GLAXO GROUP LTD (GB) | 2009-05-06 | — | — | EP | claimed |
| EP-4682248-A1 | NEW HUMAN TISSUE ORGANOID CULTURE SYSTEM | Peking University (CN) | 2026-01-21 | — | — | EP | disclosed |
| WO-2025226878-A2 | COMPOSITIONS AND METHODS FOR DELIVERING DNA | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2025-10-30 | — | — | WO | disclosed |
| WO-2024193486-A1 | NEW HUMAN TISSUE ORGANOID CULTURE SYSTEM | 北京大学 | 2024-09-26 | — | — | WO | disclosed |
| US-20240145038-A1 | cfDNA FRAGMENTOMIC DETECTION OF CANCER | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2024-05-02 | — | — | US | disclosed |
| US-20240096469-A1 | METHODS OF PREDICTING RESPONSES TO DISEASE TREATMENTS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2024-03-21 | — | — | US | disclosed |
| WO-2023243971-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DEMYELINATING DISEASE, COMPRISING KINASE INHIBITOR AS ACTIVE INGREDIENT | 고려대학교 산학협력단 | 2023-12-21 | — | — | WO | disclosed |
| WO-2022149615-A1 | CULTURE MEDIUM FOR EXPANSION CULTURE OF NEPHRON PROGENITOR CELL, METHOD FOR PERFORMING EXPANSION CULTURE OF NEPHRON PROGENITOR CELL, AND METHOD FOR PRODUCING KIDNEY ORGANOID | 国立大学法人京都大学 | 2022-07-14 | — | — | WO | disclosed |
| WO-2015070027-A1 | USE OF IKK EPSILON INHIBITORS TO ACTIVATE NFAT AND T CELL RESPONSE | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2015-05-14 | — | — | WO | disclosed |
| EP-2259787-A2 | IKKI INHIBITOR THERAPIES AND SCREENING METHODS, AND RELATED IKKI DIAGNOSTICS | The Regents of the University of Michigan (US) | 2010-12-15 | — | — | EP | disclosed |
| US-20090304714-A1 | IKKi Inhibitor Therapies and Screening Methods, and Related IKKi Diagnostics | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-12-10 | — | — | US | disclosed |
| WO-2009120801-A2 | IKKI INHIBITOR THERAPIES AND SCREENING METHODS, AND RELATED IKKI DIAGNOSTICS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-10-01 | — | — | WO | disclosed |
| EP-1720864-B1 | BENZIMIDAZOL SUBSTITUTED THIOPHENE DERIVATIVES WITH ACTIVITY ON IKK3 | GLAXO GROUP LTD (GB) | 2009-05-06 | — | — | EP | disclosed |
| US-20070149519-A1 | Benzimidazol substituted thiopene derivatives with activity on ikk3 | GLAXO GROUP LIMITED (GB) | 2007-06-28 | — | — | US | disclosed |
| US-20070149519-A1 | Benzimidazol substituted thiopene derivatives with activity on ikk3 | GLAXO GROUP LIMITED (GB) | 2007-06-28 | — | — | US | disclosed |
| US-20070149519-A1 | Benzimidazol substituted thiopene derivatives with activity on ikk3 | GLAXO GROUP LIMITED (GB) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090304714-A1 | IKKi Inhibitor Therapies and Screening Methods, and Related IKKi Diagnostics | NFKBIA, IKBKE, IRAK4 | IKBKE 2/4885PLK1 496/4885TBK1 9/4885 |
| US-20070149519-A1 | Benzimidazol substituted thiopene derivatives with activity on ikk3 | IKBKE, IKBKB, TBK1 | IKBKE 1/4885PLK1 1088/4885TBK1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.